A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Trial Profile

A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs IMC gp100 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Immunocore
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2017 According to Immunocore media release, data will be presented at the the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
    • 09 Nov 2016 Preliminary results published in the Immunocore Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top